MA30922B1 - Anticorps d'agonistes de trkb et leurs utilisations - Google Patents

Anticorps d'agonistes de trkb et leurs utilisations

Info

Publication number
MA30922B1
MA30922B1 MA31923A MA31923A MA30922B1 MA 30922 B1 MA30922 B1 MA 30922B1 MA 31923 A MA31923 A MA 31923A MA 31923 A MA31923 A MA 31923A MA 30922 B1 MA30922 B1 MA 30922B1
Authority
MA
Morocco
Prior art keywords
agonist antibodies
trkb agonist
trkb
antibodies
methods
Prior art date
Application number
MA31923A
Other languages
English (en)
Inventor
Yan Wang
Steven B Cohen
Marc Nasoff
Original Assignee
Irm Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Irm Llc filed Critical Irm Llc
Publication of MA30922B1 publication Critical patent/MA30922B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'INVENTION CONCERNE DES AGONISTES D'ANTICORPS DE TRKB ET LEURS PROCÉDÉS D'UTILISATION.
MA31923A 2006-11-09 2009-05-27 Anticorps d'agonistes de trkb et leurs utilisations MA30922B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US85816906P 2006-11-09 2006-11-09

Publications (1)

Publication Number Publication Date
MA30922B1 true MA30922B1 (fr) 2009-11-02

Family

ID=39365312

Family Applications (1)

Application Number Title Priority Date Filing Date
MA31923A MA30922B1 (fr) 2006-11-09 2009-05-27 Anticorps d'agonistes de trkb et leurs utilisations

Country Status (27)

Country Link
US (1) US20100150914A1 (fr)
EP (1) EP2087007A2 (fr)
JP (1) JP2010509354A (fr)
KR (1) KR20090088896A (fr)
CN (1) CN101573381A (fr)
AR (1) AR063640A1 (fr)
AU (1) AU2007316418A1 (fr)
BR (1) BRPI0719000A2 (fr)
CA (1) CA2669205A1 (fr)
CL (1) CL2007003236A1 (fr)
CO (1) CO6180432A2 (fr)
CR (1) CR10779A (fr)
DO (1) DOP2009000102A (fr)
EA (1) EA200970469A1 (fr)
EC (1) ECSP099392A (fr)
IL (1) IL198468A0 (fr)
MA (1) MA30922B1 (fr)
MX (1) MX2009004881A (fr)
NI (1) NI200900081U (fr)
NO (1) NO20092217L (fr)
PE (1) PE20081168A1 (fr)
RU (1) RU2009121641A (fr)
SM (1) SMAP200900040A (fr)
TN (1) TN2009000181A1 (fr)
TW (1) TW200829270A (fr)
WO (1) WO2008058127A2 (fr)
ZA (1) ZA200902943B (fr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20100089851A (ko) * 2007-10-23 2010-08-12 노파르티스 아게 호흡기 질환의 치료를 위한 ｔｒｋｂ 항체의 용도
JP5420568B2 (ja) * 2008-01-17 2014-02-19 アイアールエム・リミテッド・ライアビリティ・カンパニー 改良された抗ＴｒｋＢ抗体
EP2408455B1 (fr) * 2009-03-20 2014-06-04 INSERM (Institut National de la Santé et de la Recherche Médicale) Inhibiteurs de la cathepsine pour la prévention ou le traitement de troubles liés à l'obésité
GB2491106A (en) * 2011-05-18 2012-11-28 Univ Basel Antibodies against tropomyosin-related kinase B receptors
WO2013083826A2 (fr) * 2011-12-09 2013-06-13 Novo Nordisk A/S Agonistes du glp-1
CN102901815B (zh) * 2012-11-05 2014-10-22 武汉远征世纪制药有限公司 一种检测TrkB受体816/817位酪氨酸位点活性的ELISA试剂盒及其使用方法
CN102944674B (zh) * 2012-11-05 2014-10-22 武汉远征世纪制药有限公司 一种检测TrkB受体pan-Tyr位点活性的ELISA试剂盒及其使用方法
WO2015173756A2 (fr) 2014-05-16 2015-11-19 Pfizer Inc. Anticorps bispécifiques
CN104524568B (zh) * 2015-01-08 2018-04-20 中国人民解放军第二军医大学 一种治疗肥胖症的药物组合物及其应用
EP3328898B8 (fr) * 2015-07-28 2024-04-10 6452728 Canada Corp. Compositions d'agoniste trkb ou trkc et méthodes de traitement de troubles otiques
TW201730206A (zh) * 2015-11-17 2017-09-01 葛蘭素史克智慧財產發展有限公司 用於治療神經及其他疾病之結合激動劑
US9914781B1 (en) 2016-11-08 2018-03-13 Glaxosmithkline Intellectual Property Development Limited Binding agonist for treatment of neurological and other disorders
WO2018195008A1 (fr) * 2017-04-21 2018-10-25 Mellitus, Llc Procédés et anticorps pour des applications liées au diabète
US10793634B2 (en) * 2017-06-09 2020-10-06 Boehringer Ingelheim International Gmbh Anti-TrkB antibodies
KR102986081B1 (ko) 2017-11-30 2026-07-06 리제너론 파아마슈티컬스, 인크. 항-trkb 모노클로날 항체 및 이의 사용 방법
WO2019165421A1 (fr) * 2018-02-26 2019-08-29 Minerva Biotechnologies Corporation Procédés de diagnostic utilisant des anticorps anti-muc1*
CN110818797B (zh) * 2018-08-09 2022-11-04 东莞市朋志生物科技有限公司 一种抗人ca153蛋白的重组抗体
TW202233668A (zh) 2020-10-21 2022-09-01 德商百靈佳殷格翰國際股份有限公司 用於治療眼部疾病之雙特異性抗-VEGF及抗-TrkB結合分子
WO2023125485A1 (fr) * 2021-12-28 2023-07-06 4B Technologies (Beijing) Co., Limited Anticorps trkb et son application

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE68927933T2 (de) 1988-09-02 1997-08-14 Dyax Corp Herstellung und auswahl von rekombinantproteinen mit verschiedenen bindestellen
AU7247191A (en) 1990-01-11 1991-08-05 Molecular Affinities Corporation Production of antibodies using gene libraries
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
PT100379B (pt) 1991-04-10 1999-01-29 Scripps Research Inst Bibliotecas de receptores heterodimericos usando fagomideos
PT1024191E (pt) 1991-12-02 2008-12-22 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
JPH09506262A (ja) 1993-12-08 1997-06-24 ジェンザイム・コーポレイション 特異的抗体の製造方法
ES2201097T3 (es) 1994-01-31 2004-03-16 Trustees Of Boston University Bibliotecas de anticuerpos policlonales.
US5601820A (en) * 1994-07-07 1997-02-11 Children's Hospital Of Philadelphia Compositions and methods of making and using human full length TRK-B
MX2007015292A (es) * 2005-06-06 2008-02-21 Wyeth Corp Anticuerpos monoclonales anti-trkb y sus usos.
AU2007210862A1 (en) * 2006-02-02 2007-08-09 Rinat Neuroscience Corp. Methods for treating unwanted weight loss or eating disorders by administering a trkB agonist
JP2009525319A (ja) * 2006-02-02 2009-07-09 ライナット ニューロサイエンス コーポレイション ｔｒｋＢアンタゴニストを投与することにより肥満を治療する方法

Also Published As

Publication number Publication date
WO2008058127A9 (fr) 2008-08-21
DOP2009000102A (es) 2010-10-31
CN101573381A (zh) 2009-11-04
RU2009121641A (ru) 2010-12-20
CA2669205A1 (fr) 2008-05-15
JP2010509354A (ja) 2010-03-25
TN2009000181A1 (en) 2010-10-18
SMAP200900040A (it) 2010-01-19
ECSP099392A (es) 2009-07-31
PE20081168A1 (es) 2008-09-22
EA200970469A1 (ru) 2010-04-30
TW200829270A (en) 2008-07-16
AU2007316418A1 (en) 2008-05-15
MX2009004881A (es) 2009-05-21
WO2008058127A3 (fr) 2008-10-02
CO6180432A2 (es) 2010-07-19
US20100150914A1 (en) 2010-06-17
WO2008058127A2 (fr) 2008-05-15
NI200900081U (es) 2010-03-16
EP2087007A2 (fr) 2009-08-12
CL2007003236A1 (es) 2008-06-13
BRPI0719000A2 (pt) 2013-12-10
KR20090088896A (ko) 2009-08-20
AR063640A1 (es) 2009-02-04
ZA200902943B (en) 2010-05-26
NO20092217L (no) 2009-06-09
IL198468A0 (en) 2011-08-01
CR10779A (es) 2009-07-03

Similar Documents

Publication Publication Date Title
MA30910B1 (fr) Anticorps et immunoconjugues, et leurs utilisations
MA32535B1 (fr) Compositions et procédés pour des anticorps ciblant une protéine du complément c5
MA30153B1 (fr) Anticorps anti-ox40l et methodes correspondantes
MA30497B1 (fr) Anticorps et immunco-conjugues, et leurs utilisations.
MA30945B1 (fr) Anticorps anti-tat226 et immunoconjugués
MA29528B1 (fr) Agents de fixation
MA31231B1 (fr) Anticorps anti-robo4 et utilisations de ceux-ci
NO20083397L (no) Anti-EphB4-antistoffer og fremgangsmater for anvendelse av disse
MA33256B1 (fr) Anticorps et immunoconjugués anti-fcrh5 et procédés d'utilisation
EP2032159A4 (fr) Combinaison d'anticorps de fc riib et d'anticorps spécifiques de cd20 et leurs procédés d'utilisation
FR15C0048I1 (fr) Anticorps antagonistes de il-17
TN2009000181A1 (en) Agonist trkb antibodies and uses thereof
MA34749B1 (fr) Anticorps anti-récepteur de la barrière hémato-encéphalique à faible affinité et leurs utilisations
MA34818B1 (fr) Anticorps anti-pcsk9 et procédés d'utilisation
MA30684B1 (fr) Anticorps anti-mn et leurs procedes d'utilisation.
EP1915177A4 (fr) Anticorps d'alpha-synucléine et techniques associées
EP1964852A4 (fr) Anticorps anti-ilt7
MA33210B1 (fr) Nouveaux anticorps anti-a5b1 et leurs utilisations
EP2121008A4 (fr) Utilisations de l'anticorps monoclonal 8h9
PA8850201A1 (es) Combinaciones antitumorales que contienen anticuerpos
CL2008002885A1 (es) Anticuerpo anti-receptor de interleucina-6 (il-6); y composicion farmaceutica que lo comprende
PA8849901A1 (es) Combinaciones antitumorales que contienen anticuerpos que reconocen específicamente cd38 y la citarabina
EP2322562A4 (fr) Anticorps monoclonal et immunodosage l'utilisant
EP2007899A4 (fr) Anticorps dirigés contre la protéine 4 du type angiopoiétine et utilisations de ceux-ci
HN2006015949A (es) Anticuerpos de p-caderina